As the major malignant tumors in the chest, non-small cell lung cancer (NSCLC) and
esophageal cancer (EC) bring huge health burden to human beings worldwide. Currently …

Preoperative neoadjuvant therapy is widely used in cancer treatment; however, its efficacy in
different subtypes of non‑small cell lung cancer (NSCLC) is unknown. The present study …

Compared with postoperative adjuvant therapy, neoadjuvant therapy has more potential
advantages, such as decreasing tumor stage, killing micrometastatic cells. Because of these …

Lung cancer is the most commonly diagnosed cancer and is also the leading cause of
cancer-related mortality in the USA. More people die from lung cancer than from colorectal …

Introduction Survival rates for early-stage non-small cell lung cancer (NSCLC) remain poor
despite the decade-long established standard of surgical resection and systemic adjuvant …

Background and objective Lung cancer is the leading form of cancer in terms of both
incidence and cancer-related deaths. For patients with resectable IIIa/N2 non-small cell lung …

Neoadjuvant Therapy in Non–Small Cell Lung Cancer - Surgical Oncology Clinics Skip to
Main Content Skip to Main Menu Advertisement Surgical Oncology Clinics Log in Register Log …

Objective: Neoadjuvant chemotherapy has increased the survival benefit of non-small cell
lung cancer (NSCLC) patients. The effects of different neoadjuvant therapies are still …

Lung cancer is the leading cause of cancer death worldwide. Non-small cell lung cancer
(NSCLC) accounts for 80–85% of lung carcinomas. Approximately one-third of NSCLC …

Esophageal cancer is one of the most commonly diagnosed malignant tumors, especially in
north China. Surgery is one of the major treatments. However, for locally advanced cases …